Aim. To study efficacy and safety of beta-blocker with vasodilating properties carvedilol (Acridilole, Akrihin, Russia) as a part of the combined therapy of patients with arterial hypertension (HT) and diabetes mellitus 2 type (DM2) and/or obesity ...
Yu. V. Yu.V. Lukina+3 more
doaj +3 more sources
Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure [PDF]
This study aimed to compare the effect of β-blocker dose and heart rate (HR) on mortality in patients with heart failure with reduced ejection fraction (HFrEF).
Ajam, Samer+4 more
core +1 more source
Matrix metalloproteinase 2 (MMP-2) is activated in hearts upon ischemia-reperfusion (IR) injury and cleaves sarcomeric proteins. It was shown that carvedilol and nebivolol reduced the activity of different MMPs.
Monika Skrzypiec-Spring+10 more
semanticscholar +1 more source
Aim. To compare two therapies based on carvedilol or metoprolol in hypertensive patients with overweight and obesity.Material and methods. 320 patients with arterial hypertension (1-2 degree) were involved in the study.
S. Y. Martsevich+26 more
doaj +3 more sources
Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias
The study investigates the prognostic role of treatment with carvedilol as compared to metoprolol in patients with ventricular tachyarrhythmias. A large retrospective registry was used including consecutive patients on beta-blocker (BB) treatment with ...
Tobias Schupp+7 more
doaj +1 more source
The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist [PDF]
Nebivolol, a third generation β-adrenoceptor (β-AR) antagonist (β-blocker), causes vasodilation by inducing nitric oxide (NO) production. The mechanism via which nebivolol induces NO production remains unknown, resulting in the genesis of much of the ...
Andresen, Bradley T.+9 more
core +3 more sources
The harmonic mean $χ^2$ test to substantiate scientific findings [PDF]
Statistical methodology plays a crucial role in drug regulation. Decisions by the FDA or EMA are typically made based on multiple primary studies testing the same medical product, where the two-trials rule is the standard requirement, despite a number of shortcomings. A new approach is proposed for this task based on the (weighted) harmonic mean of the
arxiv +1 more source
Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry [PDF]
Background: To use CLARIFY, a prospective registry of patients with stable CAD (45 countries), to explore heart rate (HR) control and beta-blocker use.<p></p> Methods: We analyzed the CLARIFY population according to beta-blocker use via ...
Abergel, Hélène+10 more
core +1 more source
Effectiveness and Dose of Carvedilol Therapy In Children with Dilated Cardiomyopathy: A Prospective Randomized Double-Blinded Trial [PDF]
Background: The efficacy and safety of the beta blocker carvedilol in pediatric patients with chronic heart failure (CHF) has not been fully established till now.
Zeinab S. Seliem+5 more
doaj +1 more source
Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs [PDF]
AIMS: We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA. Carvedilol is known
Chen, Peng-Sheng+4 more
core +1 more source